Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

September’s top stories: Oncternal begins TK216 trial, Medical cannabis trials begin in Canada

Oncternal Therapeutics began dosing patients in its Phase I clinical trial of TK216 to treat Ewing sarcoma and Tilray and University of British Columbia began patient enrolment in Canada’s first Phase II clinical trial of medical cannabis to treat post-traumatic stress disorder. Drugdevelopment-technology.com wraps up the key headlines from September 2016.

Go Top